Clinical Efficacy And Safety Analysis Of Camrelizumab In The Treatment Of Advanced Esophageal Squamous Cell Carcinoma

Objective To explore the efficacy and safety of Camrelizumab treatment in patients with advanced esophageal squamous carcinoma.Methods We collected patients with advanced esophageal squamous carcinoma who used to hospitalize in our hospital from June 2019 to August 2020.To divide them into two groups,by the treatment perscriptions they received.The Control group has intravenously received docetaxel,the treatment group has intravenously received docetaxel as well as Camrelizumab.Then we observe the efficacy and safety of the two groups,Response Evaluation Criteria in Solid Tumors,version 1.1 and Common Terminology Criteria for Adverse Events,version 4.0 were used to evaluate efficacy and adverse effects.Results :A total of 62 patients were included in this analysis,the basic items between the two groups are comparable(P>0.05).As for the efficacy,There are no sense between the two groups in complete response(CR)and partial response(PR)(P>0.05).However,there were statistical significances in stable disease(SD)and progressive disease(PD)(P=0.036 and 0.005).The Objective Respondse Rate(ORR)and The Disease Control Rate(DCR)of the Control group is 15.62% and40.62%,which is 23.33% and 76.66% in the treatment group.As for the survival time,the treatment group has longer lifetime than the Control group,and the Chi-square value is 4.098(P=0.043),the overall survival time of the former is 11 months,which is 3 months more than the latter.As for the median survival time,the Chi-square value is 5.730(P=0.017),the median survival time of the former is 8 months which is 2months more than the latter.The most common toxicity reactions were hypothyroidism,fervescence,hypodynamicy,gastroenteric reaction,anemia,all of the toxicity reactions are level I-II,None of the patients died of toxicity reactions.Conclusion:The efficacy and safety of Camrelizumab used in patients with advanced esophageal squamous carcinoma are affirmatory.Camrelizumab can prolong the survival time of patients as well,which is worth to be promoted in the future.